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Abstract
To examine the hypothesis that normalization of low circulating leptin levels in patients with anorexia nervosa
ameliorates hyperactivity, three seriously ill females with hyperactivity were treated off-label with metreleptin
(recombinant human leptin) for up to 14 days. Drive for activity, repetitive thoughts of food, inner restlessness, and
weight phobia decreased in two patients. Surprisingly, depression improved rapidly in all patients. No serious adverse
events occurred. Due to obvious limitations of uncontrolled case series, placebo-controlled clinical trials are mandatory
to confirm the observed rapid onset of beneficial effects. Our findings suggest an important role of hypoleptinemia in
the mental and behavioral phenotype of anorexia nervosa.
Introduction
Underweight, fear of weight gain, and body image dis-
turbances represent cardinal features of anorexia nervosa
(AN)1,2. Somatic, mental and behavioral symptoms of this
eating disorder are intertwined with those of starvation3,
which develops from the prolonged energy restriction
characteristic of AN2,4. Loss of fat mass in AN entails a
drop in blood levels of the adipocyte-derived hormone
leptin5. Ensuing hypoleptinemia represents a key endo-
crine feature of this eating disorder3,6,7 and acts as the
major signal for the adaptation to starvation7–10. Ame-
norrhea, hematological alterations, depressed mood,
inflexibility, and repetitive thoughts of food represent
clinically relevant examples of starvation-related symp-
toms, which might be triggered or worsened by
hypoleptinemia5.
Hyperactivity is a common behavioral manifestation of
AN, which has also been linked to hypoleptinemia11–14,
albeit not consistently so15. Rodent studies point to a
causal link between hyperactivity and low circulating
leptin levels11,16–18. In rats, semi-starvation induced
hyperactivity proved to be rapidly amenable to treatment
with recombinant leptin in one study11, but not in
another19. In light of the potential involvement of the
reward system in AN20–26, the role of leptin as a strong
modulator of this system deserves attention5,14,16,27–30
within the context of AN specific psychopathology.
We hypothesized that hyperactivity, but potentially also
starvation-related emotional, cognitive, and somatic
symptoms in patients with AN may be alleviated by off-
label treatment with metreleptin5, a recombinant analog
of human leptin. Metreleptin has been approved by the
Food and Drug Administration and the European Medical
Agency for the treatment of metabolic abnormalities in
congenital or acquired generalized lipodystrophy5,31,32.
Metreleptin has also been used to successfully treat a
small number of patients with inborn leptin deficiency33–35,
inducing a rapid reduction of hunger and substantial
weight loss over time, as well as a normalization of
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metabolic and hormonal functions. Two studies, includ-
ing a double-blind randomized controlled trial (RCT),
revealed an improved reproductive function in females
with hypothalamic amenorrhea36,37. Another RCT
showed an increment of bone mineral content in
strenuously exercising young women with hypoleptine-
mia38. In general, metreleptin is well tolerated. However,
medium-term slight weight loss has been observed36,
which in single patients can entail the cessation of treat-
ment after several weeks37,38.
Based on the aforementioned considerations we for the
first time treated three seriously ill patients with AN and
pronounced hyperactivity with metreleptin. Such a case
series, which according to German and Swiss regulatory
requirements can only be conducted with a very limited
number of patients outside of a clinical trial39,40, aimed to
probe potential clinical effects of metreleptin treatment.
Such efforts are clearly warranted in light of the overall
limited effects of current off-label treatments for AN41.
Thus, whereas drugs such as e.g. antidepressants42 and
antipsychotics43 are widely prescribed for symptoms of
AN, including hyperactivity44,45, the evidence-base for
their effectiveness is meagre2,42,43,46.
Patients and methods
Setup and pre-treatment evaluation
Two adult female inpatients (A, B) were treated at the
Eating Disorders Unit, University Hospital Zurich, Swit-
zerland, an adolescent female inpatient (C) at the
Department of Child and Adolescent Psychiatry in Essen,
Germany. All three patients suffered from intermittently
life-threatening AN diagnosed according to DSM-5
(Table 1). This illness severity was also experienced by
the patients themselves and represented the overarching
inclusion criterion for the off-label treatment. All three
patients subjectively complained about their drive for
activity; the clinically apparent hyperactivity was rated as
pronounced by the treatment teams (see Figs. 1 and 2,
Supplemental Figs. 1 and 2, and clinical interview with
patient A in Supplementary video; written informed
consent was obtained).
For patient B, the local therapeutic team had considered
palliative treatment after consultation with a clinical ethicist
because of treatment refractory AN. The initiation of dosing
was postponed twice due to somatic instability. One day
prior to dosing, she was transferred back to the Eating
Disorders Unit after a 2-week treatment in the internal
medicine ward, including nasogastric feeding, to achieve a
stable somatic condition. In light of pre-relapse under-
weight in patient A, patient C was additionally selected for
premorbid obesity. She was intermittently transferred to
Essen for a total of twelve days from a hospital in the region.
To allow for pre- and post-treatment assessment the dosing
period lasted six days only.
Weight gain represented a central goal of the inpatient
treatment regimens prior, during and after metreleptin
treatment. Patients were treated as usual in the two
interdisciplinary and multimodal eating disorder treat-
ment programs and were requested to follow a defined
daily meal plan including a specified energy intake to
achieve weight gain. All patients received three main
courses and three interim meals per day with between
2700 and 3000 kcal/day.
During the entire observation periods including (i) pre-
dosing, (ii) dosing, and (iii) follow-up, body weights of
patients were not measured daily; weights clearly vacillated
throughout (Supplementary Table 1). We chose the closest
weight measurements prior to and upon completion of
dosing as body weights at T0 and T1 (see Table 2 and
Supplementary Table 1); an exception due to excessive
drinking to “reduce appetite” was made for patient C, for
whom we used the realistic weight 2 days after end of
dosing (d+ 2). Prior to dosing, only two patients (A:
+5.8 kg, C: +10.9 kg) had gained weight (Tables 1 and 2;
Supplementary Table 1); patient C had, however, vacillated
between 42 and 44 kg in the 4 weeks prior to dosing with a
single peak at 45 kg due to water ingestion (see above).
All contacted patients agreed to participate; a fourth
patient who had been informed of the treatment, was
unable to declare her unequivocal consent. Due to safety
precautions, dosing periods were a priori limited to ten
days with the possibility of an extension for an additional
week in case of subtle treatment effects only.
All patients and parents of the 17-year old (C) provided
written informed consent to off-label metreleptin treat-
ment. Patient A received the information that the treat-
ment aim was to reduce her severe hyperactivity. Based on
these initial observations patients B and C were addi-
tionally informed about the possible antidepressant effect
and the reduction of eating disorder specific cognitions.
Patients (and parents) were instructed that non-
adherence to requirements of the therapeutic team,
including a specified daily total energy intake, could lead
to discontinuation. The off-label treatment5 had been
discussed and agreed upon by local and external physi-
cians (G.M., J.H., S.T., N.B., R.v.K., M.W.); a medical
ethicist (U.W.) provided ethical guidance. The off-label
treatment was in accordance with the latest version of the
Declaration of Helsinki47,48.
Clinical assessment
All patients filled in a 10-item visual analog scale (VAS;
scaled 1–10) for the assessment of key cognitions, emo-
tions, and safety/physiological items twice or thrice daily
(means presented in Figs. 1 and 2 and Supplementary
Figs. 1 and 2 (patient B); no diurnal patterns for any item
were observed); the ten items were ranked as follows:
hunger, repetitive thoughts of food, fear of weight gain,
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Family history Maternal MDD and unspecified eating disorder AN in maternal uncle Parental obesity
Previous hospitalizations for AN N 1 5 4
Age at Years
Referral 26 19 17
Onset of AN 15 13 14
Menarche 15 Primary amenorrhea 12
Maximum lifetime weighta 14 15 14
Minimum weight during AN 26 17 16
Weight kg
At referral 30.0 36.0 32.0
Maximum lifetimeb 45.0 42.0 97.0
Minimum during AN 30.0 30.7 32.0
Height at referral cm 162 164 166
BMI at kg/m²
Referral 11.4 13.4 11.6
Maximum lifetimec 17.1 15.6 35.2




Days 9 14 6
Dosesd mg/day 4-6-7.5-10-10-0-10-0-10 2-2-3-3-4.5-6-6-8-0-10-0-11.3-0-11.3 6-9-9-9-9-9
Concurrent medication and
daily doses
Aripiprazole 10 mg, fluoxetine 60 mg,
diazepam 5mge, etilefrine hydrochloride 20 mg,
multivitamin tablets with iron






Severe AN; hyperactivity experienced as agonizing and
compulsive; MDD
Severe AN; hyperactivity, MDD; palliative care considered in light




































drive for activity, inner tension, feeling full, nausea, feel-
ing fat, depressed mood, tiredness. All patients were
additionally assessed with the Hamilton Depression
Scale-1749 (HAMD-17) by non-blinded clinical raters.
Self-rating scales included Eating Disorders Inventory
(EDI50; to allow comparisons with population-based
norms we present percentile ranks50,51) and Beck
Depression Inventory-II (BDI-II)52. Patients A and B also






































































































































































































































































































































































































































Fig. 1 VAS for key cognitions and emotions: Effects of short-term
metreleptin treatment in patient A including follow-up observations
for 14-days, showing means of six key cognitions and emotions
assessed thrice daily with visual analog scales (range 1–10).
Fig. 2 VAS for key cognitions and emotions: Effects of short-term
metreleptin treatment in patient C including follow-up observations
for 14-days, showing means of six key cognitions and emotions
assessed twice daily with visual analog scales (range 1–10).
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Table 2 Safety, self- and clinician rated psychological data for patients A–C prior (T0) and at end of metreleptin
treatment (T1) and serum leptin levels at T0 and during treatment.
Patient
A B C
T0 T1 T0 T1 T0 T1
Safety data
Body weight kg 35.8 37.0 32.9 33.6 42.9 42.7
BMI kg/m2 13.6 14.1 12.2 12.5 15.6 15.5
Pulse (range) 52–72 61–84 68–76 72–72 52–77 57–64
Systolic/diastolic blood pressure
(range)
mmHg 85/55–90/70 85/55–95/60 90/65–95/60 80/60–90/60 75/60–113/58 100/60–105/70
Body temperature (range) oC 36.2–37.1 36.1–37.3 35.2–36.0 35.6–36.8 36.5a 35.8a
Serum glucose (range) mmol/l 4.6–5.1 5.1–6.5 3.8–4.3 4.8–5.1 4.8–6.2 4.1–6.6
Leucocytes /nl 4.59 6.12 2.1 3.2 3.29 4.74
Lymphocytes /nl 0.73 0.91 0.83 1.06 0.7 1.38
Erythrocytes /nl 3.38 3.63 3.27 3.29 4.48 4.71
Thrombocytes /nl 235 266 231 208 247 192
GOT U/l 25 35 38 32 22 34
GPT U/l 13 43 60 28 44 47
Amylase U/l 70 68 44 53 54 69














BDI-II 34 15 37 27 37 6
EDI-2 Percentile rank
Total score 84 87 87 87 99 80
Drive for Thinness 75 75 85 90 99 75
Bulimia 1 99 1 1 99 45
Body Dissatisfaction 45 10 55 55 95 75
Ineffectiveness 99 85 95 95 99 80
Perfectionism 75 10 70 70 90 70
Interpersonal Distrust 95 55 80 85 60 50
Interoceptive Awareness 65 99 95 90 99 85
Maturity Fears 40 90 70 80 99 99
EDE-Qb
Total score 3.11 2.48 3.62 3.53
Restraint 2.4 2.4 3.2 3.4
Eating Concern 1.2 0.6 2.4 2.4
Weight Concern 3.6 1.8 3.8 3.2
Shape Concern 5.25 5.13 4.88 5.13
Clinician ratings
HAMD-17 29 12 22 15 31 14
Leptin serum levelsc
T0 ng/ml <0.5 <0.5 <0.1
During treatment 3 time points:
ng/ml 72.9 4.4 6.7 55.9 80.8
Treatment day 7 13 2 4 5
Last dose mg 10 11.3 6 9 9
Hours after sc. applicationd 7 22 22 2 4
NAD no abnormality detected, BDI-II Beck Depression Inventory-II, BMI body mass index, EDI-2 Eating Disorder Inventory-2, HAMD-17 Hamilton Depression Scale-17, s.c
subcutaneous.
aMeasured once daily only.
bInstructions were adapted to shortened observation time.
cLeptin assays for determination of total leptin serum concentrations: Leptin ELISA assay E07 (Mediagnost GmbH, Reutlingen, Germany; for patients A and B) and
Leptin ELISA assay MD53001 (IBL International GmbH, Hamburg, Germany; patient C).
dFor metreleptin a half-life of 3.8–4.7 h and a median tmax of 4 h (range 2–6 h) following s.c. administration was reported in patients with lipodystrophy
32.
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(EDE-Q)53; they were requested to base their answers on
the last 7 days (instead of the last 28 days; instructions
were adapted to the shortened observation time). Patients
were clinically monitored during treatment (Table 2).
Treatment
Metreleptin was applied subcutaneously (thigh) once
daily at 9:30 am; dosage recommendations for patients
with lipodystrophy served as guidance32. In patient A, the
maximum dosage of 10mg was reached at day four (Table 1).
For patient B, who was the most acutely ill patient with
the lowest body mass index (BMI) at baseline, the dosage
was slowly titrated for safety concerns; she received the
highest dosage of 11.3 mg on days twelve and fourteen.
Based on the observed, uncomplicated courses of patients
A and B, patient C was titrated to the maximal dose of
nine mg at day two. Metreleptin was intermittently dis-
continued in patients A and B (Table 2).
Results
Two days after initiation of dosing, patients A and C
began to rank most VAS items for key cognitions and
emotions as less severe (Figs. 1 and 2). In the following
days, the downward trend continued toward a plateau
with low values. Whereas the overall effect was similar,
quantitative differences were observed at the level of each
item. Patient B reported no changes in the VAS (see
Supplementary Fig. 1). Dosing did not affect self-rated
(VAS; Figs. 3 and 4) safety/physiological items system-
atically in any patient.
During dosing periods, patients A and B gained 1200
and 700 grams, respectively; patient C lost 200 grams
(Table 2); hunger was continuously rated as (almost)
absent (Fig. 4). Fear of gaining weight, which was initially
rated maximal by patient A, decreased during dosing (Fig. 1).
Depressed mood, inner tension, and drive for activity
increased in patient A during the 14 day long post-dosing
observation period; fear of weight gain did not rebound.
In patient C fear of weight gain and feeling fat rebounded
(Fig. 2).
Self-rated depressive symptoms (BDI-II) decreased in all
patients with patients A and especially C showing sub-
stantially lower values (Table 2). While the total EDI score
improved only in patient C, the clinician-rated HAMD-17
revealed reductions in depressive symptoms in all
patients. Patient A reported a clear improvement of her
EDE-Q score; in patient B the improvement was marginal.
Circulating leptin levels (total-leptin), which were
initially in the very low range characteristic for patients
with acute AN6, reached high levels two to seven hours
after metreleptin application, and were in the low normal
range in the morning prior to the next dosing.
Increments were observed for leucocytes and lympho-
cytes in all patients. Pulse, blood pressure, body tem-
perature, blood glucose, and other laboratory parameters
revealed no systematic changes (Table 2).
Serious adverse events were not observed. In patient A,
the upswing in mood was so pronounced, that dosing was
discontinued on two days (Table 1). The patient herself
reported a “happiness” equivalent to her lifetime maxima
(see Supplementary video). She stopped taking diazepam
because she no longer dreaded meals; she was surprised
by the fact that she was able to phone lying relaxed in bed,
for months she always did everything standing. Patient C
experienced extended night sleeps and naps, which she
experienced as healthy. Accordingly, treatment with
melperone and olanzapine was terminated at days three
and four, respectively.
Fig. 3 VAS for safety and physiology: Effects of short-term metreleptin
treatment on four self-ranked safety/physiological parameters in
patient A assessed thrice daily with visual analog scales (range 1–10).
Fig. 4 VAS for safety and physiology: Effects of short-term metreleptin
treatment on four self-ranked safety/physiological parameters in
patient C assessed twice daily with visual analog scales (range 1–10).
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Six months after treatment, patient A had achieved her
lifetime maximal BMI of 20 kg/m2; her menses had
resumed; she was well integrated in everyday life. She had
intermittently developed panic attacks and a temporary
episode of major depression, both of which had also
occurred prior to referral. Patients B and C were dis-
charged at days +33 and +24 due to failure to gain weight
with BMIs of 12.4 kg/m2 and 15.9 kg/m2. Both are cur-
rently being treated on an outpatient basis.
Clinical observations
During dosing, hyperactivity decreased only slightly in
patient B, but substantially in patients A and C based on
clinical observations of the treatment teams. For example,
patient A was able to sit for 30 min for the purpose of an
interview and intermittently lean back (see Supplemen-
tary video). Patient C, who would usually get up at 5 am
prior to dosing to exercise, had to be wakened at 7.30 am
after treatment for three days; she also took naps during
the afternoon. Both patients reported a more “realistic”
assessment of body shape and weight; they explained that
metreleptin treatment allowed them to think outside the
“cage” meaning that they were able to view themselves
“realistically” without being constrained by their eating
disorder. Both reported a substantial boost in their
motivation to overcome AN, which patient A, but not
patient C, was able to act upon. During dosing, patient C
reported being able to discern her emotions more readily;
prior to dosing she had been overwhelmed by them.
According to her parents, she was substantially less
hyperactive and agitated, her mood improved. She reported
on dream contents unrelated to food. Despite low hunger
ratings (Fig. 4), patient C reported an increase in “appetite”
during treatment, which upset her in light of previous
episodes of binge eating (see also increment in subscale
Bulimia of EDI; Table 2). At the end of the dosing period
she explained that this increment in appetite rendered her
attitude toward metreleptin treatment more ambivalent
despite the otherwise experienced substantial improvement.
All patients reported an improved ability to concentrate.
They more readily initiated personal contacts, e.g. a
renewed desire to contact friends and relatives (patient
A), playing board games with other patients (B) and an
intense, but fruitful, discussion with her parents (C).
Patient A reported less constipation (see Supplementary
video). In patients A and C, the skin prior to sub-
cutaneous application of metreleptin appeared wrinkly
and dry. It rapidly normalized in turgor during dosing.
Patient C observed healing and initial hair growth in bald
spots due to excessive scratching.
Discussion
Whereas the decreased drive for activity supported our
primary hypothesis in our uncontrolled case series, the
compelling and rapid changes of cognitive, emotional, and
behavioral symptoms in patients A and C and to a
markedly lower degree in patient B clearly warrant ade-
quately powered double-blind and placebo-controlled
RCTs. We had hypothesized beneficial effects on hyper-
activity and starvation-related emotions and cognitions5,
but were surprised by the rapid onset, the multiplicity of
effects, the apparent effect sizes and the unexpected
decrease in AN specific cognitions such as fear of weight
gain and feeling fat. These effects seemingly allowed our
patients an intermittent escape from the ‘golden cage’54 of
their eating disorder. After cessation of metreleptin
treatment most VAS items rebounded (Figs. 1 and 2).
In light of the lack of a consistent operational definition
of hyperactivity in AN5,55, several different modes of
assessment have been used with partially conflicting
results. Because subjectively rated drive for activity may in
part reflect muscle tension, inability to relax, inner rest-
lessness, inner tension, and anxiety in addition to an
elevated physical activity55, the use of pedometers or
accelerometers does not necessarily capture the extent of
the drive for activity. For the purpose of this case series,
we used the VAS based subjective rating for drive for
activity to obtain a subjective measurement. Obviously in
future trials, both subjective and objective ratings should
be used to capture the phenomena inherent to ‘hyper-
activity´ (see ref. 12).
Patients A and B were able to gain weight during
treatment; it cannot be excluded that the weight loss of
200 grams incurred during dosing in patient C may reflect
an effect of metreleptin. However, both the short dosing
periods and the weight vacillations prior and after treat-
ment of patients B and C (Supplementary Table 1) pre-
clude any definite conclusions as to an effect of
metreleptin on body weight. Hunger was rated as absent
or minimal throughout the total observation periods. It
deserves notice that despite low hunger ratings (Fig. 4),
patient C reported an increase in “appetite” during
treatment, which clearly induced stress potentially in light
of previous episodes of binge eating. We interpret her
increased score on the EDI subscale Bulimia accordingly
(Table 2). In contrast to the well-known anorexic function
of leptin, we speculate that persistent hypoleptinemia may
induce or contribute to absence of hunger; the ther-
apeutically induced rapid resolution of hypoleptinema
may however re-trigger appetite. If this speculation is
correct, the treatment-induced appetite may render
patients ambivalent as to the continuation of treatment.
Our somatic observations merit discussion. Increments
in blood cell counts may reflect hematopoetic effects of
leptin56. In the skin, leptin has been linked to cell differ-
entiation, proliferation, migration, and survival with pro-
nounced effects on angiogenesis, blood flow, and tissue
perfusion, thus affecting skin aging, wound healing, and
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hair follicle morphogenesis57. Leptin also functions as an
important modulator of gastrointestinal tract functions58.
In light of potential interactions, concurrent medica-
tions (Table 1) impede the interpretation of our findings
as being due to metreleptin treatment only. However, it
should be noted that two neuroleptic medications of
patient C were stopped during treatment in light of the
rapidly reduced hyperactivity and her emergent ability to
rest. Patient A stopped pre-meal intake of diazepam,
which she no longer deemed necessary.
The individualized metreleptin dosing schemes were
based on safety considerations and ad hoc clinical
observations. Importantly, for regulatory and ethical rea-
sons, we were unable to consider matched, placebo trea-
ted controls. This major limitation entails that observed
improvements may (partly) represent treatment expecta-
tion (placebo) effects. Indeed, all three patients were
closely monitored and repeatedly interviewed entailing an
unusual large amount of clinical attention. The sub-
cutaneous mode of application may also have promoted
expectation effects. However, for the following reasons we
consider it highly unlikely that such effects in total explain
our results: (i) In general, AN is one of the most difficult
disorders in psychiatry to treat2,59; particularly achieve-
ment of weight gain is notoriously challenging in this
disorder4,60. In clinical terms, we are unaware of any
evidence for the occurrence of pronounced expectation
effects in acutely ill patients. Thus, both verum and pla-
cebo effects have proven rather meager in AN4, indirectly
reflected by the non-availability of any drug licensed for
the treatment of this eating disorder. (ii) Patient A had
only been informed (written informed consent) of a
potential effect of metreleptin on hyperactivity; however,
according to both her VAS rankings and clinical obser-
vations the rapid improvement of depression and the
concomitant reduction of fear of weight gain was unex-
pected and pronounced. (iii) Some effects were observed
in all three patients (improved mood, increased con-
centration, and social contacts). More subtle effects on
concentration and social interaction (both not listed in
the information sheets), were noticeable and reported by
all three patients. (iv) Overall, the effects were similar in
two patients (A and C) despite an age difference of ten
years, their treatment in two different units and pre-
morbid underweight versus obesity. (v) Interestingly,
dosing did not affect the four safety/physiological items
despite their listing on the same sheet as the other six
items (for order of items see “Patients and methods”)
indicating that patients did not merely rate all items as
changed. (vi) Somatic effects consistent with current
knowledge of the effects of leptin were observed, which
cannot be explained by expectation effects. (vii) Overall
the results were consistent with hypothesized effects of
metreleptin treatment of patients with AN5. Results of a
case series are to be judged as more reliable, if the
underlying hypothesis is well founded and has been sub-
stantiated in e.g. rodent studies61 or related observations
in humans62.
With respect to future systematic trials, important
questions relate to treatment duration, minimal effective
dose, medium-term safety and primary outcome criteria.
Our patients might have profited from longer treatment
durations. During dosing, patients A and C seemed more
amenable to psychotherapy due to their elevated moti-
vation and detachment from eating disordered cognitions.
It remains to be seen to what extent the clinical changes
enable longer-term behavioral changes and importantly
weight gain. It will prove crucial to exclude a negative
effect of metreleptin on weight gain in patients with AN.
While weight gain will remain the focus of AN treatment,
a shift toward improvement of quality of life as primary
outcome in patients with longstanding or intractable AN
has been proposed63. All of our patients had been ill for
extended time periods entailing the need to rapidly adapt
to the induced changes. Severity of starvation, pre-morbid
body-weight (Table 1), and/or type of AN1 may account
for short- and medium-term response variation. RCTs are
required to assess whether (a) patients with shorter illness
duration and less severe symptomatology may profit
more, and (b) for how long “the cage needs to be
unlocked” to allow patients—supported by standard
treatment regimens—a more permanent ‘escape’ brought
on by weight gain. The concomitant increase in fat mass
should over time entail a sufficient endogenous leptin
secretion to maintain the metreleptin induced behavioral,
emotional, and cognitive improvements. Metreleptin
treatment may initially help to overcome depression,
reduce hyperactivity, and promote insight into the eating
disorder pathology. The combined effect may increase the
therapeutic motivation to more readily allow adjustment
to the therapeutic regimen necessarily including a positive
energy balance. As endogenous leptin secretion increases
over a matter of weeks, metreleptin dosing could gradu-
ally be discontinued. Our results indirectly support weight
rehabilitation as the mainstay of AN treatment5.
Our results suggest that leptin induced alterations at the
post-receptor level result in clinically evident changes
within a matter of 24–48 h. We also assume that as long
as leptin levels stay above the critical level of ~2 µg/L (as
threshold criterion for the initiation of the endocrine
adaptation to starvation64, the restitution of a level well
above this threshold is sufficient to maintain effects.
Replication provided, AN may be recognized in part as a
hormone deficiency syndrome. Hormones influence both
cognitions and emotions with timing effects and critical
periods65. The strong female preponderance of AN and
the typical manifestation during the second decade of life
may suggest such a sex-specific critical period. The
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seemingly different pathways, through which hypolepti-
nemia evokes emotional, cognitive, and behavioral
derangements, need to be deciphered. In mice, leptin
suppresses the rewarding effects of running via activation
of signal transducer and activator of transcription-3 sig-
naling in dopaminergic neurons of the ventral tegmental
area without simultaneously affecting the anorectic
actions of leptin and hedonic and compulsive feeding
behavior16. The temporary evolution of specific cogni-
tions, emotions, and behaviors during and after metre-
leptin treatment may help to elucidate if and how they are
inter-related in patients. In a next step, it will be intri-
guing to investigate the central effects of metreleptin in
terms of functional brain connectivity before and after
treatment.
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